Vaccination is essential to prevent world's leading child killer - pneumonia
- Press Releases
- Vaccination is essential to prevent world's leading child killer - pneumonia
Vaccination is essential to prevent world's leading child killer - pneumonia
30 October 2009
Marking the first international World Pneumonia Day on 2 November, the GAVI Alliance plans to immunise 130 million children in poor countries against pneumonia, the world's leading child killer.
GAVI plan offers "historic opportunity" to immunise 130 million children and further reduce mortality
Geneva, 30 October 2009 - Marking the first international World Pneumonia Day on 2 November, the GAVI Alliance plans to immunise 130 million children in poor countries against pneumonia, the world's leading child killer.
Pneumonia, a severe inflammation of the lungs usually caused by infection, is responsible for one in four child deaths, more than HIV/AIDs, malaria and measles combined. Each year, it kills approximately 1.8 million children under five years of age, making it the leading child killer. Despite its overwhelming toll, little attention and funding are given to it.
Vaccine available
"A child dies of pneumonia every 15 seconds and 98% of those deaths are in poor nations," said Dr Julian Lob-Levyt, GAVI CEO.
"A vaccine to help protect children from pneumonia has existed since 2000 but is only available in rich countries. GAVI plans to change that," said Dr Julian Lob-Levyt, GAVI CEO.
The most effective way to prevent pneumonia deaths is to provide easy access to safe and affordable vaccines.
Vaccines against two of pneumonia's common bacterial causes, Hib (Haemophilus influenzae type b) and pneumococcus, are routinely used in industrialized countries but are not yet available in most of the developing world.
Accelerated Vaccine Introduction
Since 2001, GAVI has provided funding for the introduction of Hib vaccines in 59 countries with astonishing results. Thanks to this increased use of the vaccine, a number of countries, including Uganda, Bangladesh, and Kenya, have nearly eliminated the disease.
Lob-Levyt said GAVI's Accelerated Vaccine Introduction initiative aims to speed up the introduction of pneumococcal vaccines to vaccinate approximately 130 million children in 42 countries by 2015.
The plan also aims to introduce the vaccine against rotavirus, which causes diarrhoea, another major killer, in 44 countries. Together, the introduction of the two vaccines could save the lives of up to 11 million children by 2030.
Millennium Goal 4
To fund the plan, GAVI will need to raise up to an additional $4 billion between 2009 and 2015.
"Millennium Goal 4 cannot be met without this investment," said Lob-Levyt.
"Immunisation is one of the most cost-effective ways to save lives. And improved health is a fundamental driver for long term development. Donors and the global health community must remain focused on the cost-effective intervention of immunisation, particularly in the current economic climate. "
The objective of Millennium Goal 4, one of the eight goals set by the United Nations in 2000, is to reduce by two thirds the number of deaths of children under five by 2015.
World Pneumonia Day: November 2 2009The GAVI Alliance will join more than 50 organizations and millions of people worldwide in supporting the first-ever World Pneumonia Day to highlight pneumonia's tremendous burden and the potential of prevention and treatment solutions. The fight against pneumonia is a collective responsibility and an important step for the international community in reaching the Millennium Development Goals by 2015, including the goal to reduce the death of children under 5 by two -thirds. |
Long-term sustainable supply
The GAVI Alliance has been at the forefront of finding innovative ways to raise money for immunisation. To ensure a long-term sustainable supply of pneumococcal vaccines, Alliance members, including the World Bank and UNICEF, have developed a market-based financing mechanism called the Advance Market Commitment, or AMC.
Using donor commitments, the AMC provides an incentive for vaccine makers to produce suitable vaccines in the necessary quantities at an affordable price for developing countries. The result is that GAVI has been able to reduce the current price of existing pneumococcal vaccines by up to 90%.
Right to health
"Children in poor countries have the same right to health, the same right to be immunised, as children in rich nations," said Lob-Levy.
"We have the vaccine technology, the demand by countries and the systems in place. This is an historic opportunity to make another giant leap towards reducing child mortality in our lifetime."
Global Action Plan
The Alliance's vaccination plans are included in the Global Action Plan for the prevention and control of pneumonia (GAPP), a report to be presented by WHO and UNICEF on 2 November.
The report outlines a comprehensive prevention and control strategy to further reduce the rate of pneumonia among children. Vaccination is part of an integrated approach that includes antibiotics, oxygen therapy, adequate nutrition and clean water.
Share this article
Restricted Access Library
The material in this Restricted Access Library is intended to be accessed only by persons with residence within the territory of a Member State of the European Union and is not intended to be viewed by any other persons. The material in this Restricted Access Library is provided by IFFIm for information purposes only and the materials contained herein were accurate only as of their respective dates. Certain information in the materials contained herein is not intended to be, and is not, current. IFFIm accepts no obligation to update any material contained herein.
Persons with residence outside the territory of a Member State of the European Union who have access to or consult any materials posted in this Restricted Access Library should refrain from any action in respect of the securities referred to in such materials and are otherwise required to comply with all applicable laws and regulations in their country of residence.
By clicking Access restricted content: DYNAMIC-LINK-TEXT I confirm that I have read and understood the foregoing and agree that I will be bound by the restrictions and conditions set forth on this page.
The materials in this Restricted Access Library are for distribution only to persons who are not a "retail client" within the meaning of section 761G of the Corporations Act 2001 of Australia and are also sophisticated investors, professional investors or other investors in respect of whom disclosure is not required under Part 6D.2 of the Corporations Act 2001 of Australia and, in all cases, in such circumstances as may be permitted by applicable law in any jurisdiction in which an investor may be located.
The materials in this Restricted Access Library and any documents linked from it are not for access or distribution in any jurisdiction where such access or distribution would be illegal. All of the securities referred to in this Restricted Access Library and in the linked documents have been sold and delivered. The information contained herein and therein does not constitute an offer for sale in the United States or in any other country. The securities described herein and therein have not been, and will not be, registered under the U.S. Securities Act of 1933, as amended (the "Securities Act"), and may not be offered or sold in the United States except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and in compliance with any applicable state securities laws.
Each person accessing the Restricted Access Library confirms that they are a person who is entitled to do so under all applicable laws, regulations and directives in all applicable jurisdictions. Neither IFFIm nor any of their directors, employees, agents or advisers accepts any liability whatsoever for any loss (including, without limitation, any liability arising from any fault or negligence on the part of IFFIm or its respective directors, employees, agents or advisers) arising from access to Restricted Access Library by any person not entitled to do so.
Reflections on IFFIm: an interview with Rachel Turner
14 November 2024